PMID- 24127416
OWN - NLM
STAT- MEDLINE
DCOM- 20140612
LR  - 20220409
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 66
IP  - 5
DP  - 2014 May
TI  - Comparison of composite measures of disease activity in psoriatic arthritis using 
      data from an interventional study with golimumab.
PG  - 749-56
LID - 10.1002/acr.22204 [doi]
AB  - OBJECTIVE: To compare the performance of the Psoriatic Arthritis Disease Activity 
      Score (PASDAS), the Arithmetic Mean of the Desirability Function (AMDF), the 
      Composite Psoriatic Disease Activity Index (CPDAI), and the Disease Activity 
      Index for Psoriatic Arthritis (DAPSA) in the GO-REVEAL data set. The Disease 
      Activity Score using 28 joints (DAS28) was used as a comparator. METHODS: The 
      GO-REVEAL study did not allow full computation of all the composite scores (a 
      modified version of CPDAI was used). The performance of the scores at baseline 
      and followup (weeks 14 and 24) was compared using effect sizes. RESULTS: All 
      indices could distinguish response to treatment at 14 and 24 weeks. Effect sizes 
      at 24 weeks for the 50 mg (100 mg) golimumab doses were 2.18 (2.36), 2.08 (2.36), 
      1.09 (1.41), 1.80 (1.78), and 1.13 (1.18) for PASDAS, AMDF, modified CPDAI, 
      DAS28, and DAPSA, respectively. Comparison of 24-week values across the 3 
      treatment groups (placebo, golimumab 50 mg, and golimumab 100 mg) by an analysis 
      of covariance using the baseline values as covariates gave the following F 
      statistics: PASDAS 18.3, AMDF 19.6, modified CPDAI 9.4, DAS28 13.6, and DAPSA 
      7.9; all of these are highly significant. When the analysis was confined to the 2 
      golimumab treatment groups, there were no significant between-treatment group 
      differences with any of the composite measures. CONCLUSION: PASDAS and AMDF were 
      better able to distinguish treatment effect, having larger effect sizes at 24 
      weeks. PASDAS, AMDF, and modified CPDAI better reflected domains such as skin, 
      enthesitis, and dactylitis.
CI  - Copyright (c) 2014 by the American College of Rheumatology.
FAU - Helliwell, Philip S
AU  - Helliwell PS
AD  - University of Leeds, Leeds, UK.
FAU - Kavanaugh, Arthur
AU  - Kavanaugh A
LA  - eng
SI  - ClinicalTrials.gov/NCT00265096
GR  - G0800629/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Antibodies, Monoclonal)
RN  - 91X1KLU43E (golimumab)
SB  - IM
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Arthritis, Psoriatic/*diagnosis/*drug therapy/epidemiology
MH  - *Databases, Factual
MH  - Drug Administration Schedule
MH  - Follow-Up Studies
MH  - Humans
MH  - *Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2013/10/16 06:00
MHDA- 2014/06/13 06:00
CRDT- 2013/10/16 06:00
PHST- 2013/05/13 00:00 [received]
PHST- 2013/10/08 00:00 [accepted]
PHST- 2013/10/16 06:00 [entrez]
PHST- 2013/10/16 06:00 [pubmed]
PHST- 2014/06/13 06:00 [medline]
AID - 10.1002/acr.22204 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2014 May;66(5):749-56. doi: 10.1002/acr.22204.